Prostate cancer can progress from androgen dependence to androgen deprivation resistance with some unknown mechanisms. The current study aims to explore the possible role of pituitary tumor transforming gene1 (PTTG1) in castration-resistant prostate cancer (CRPC). Initially, we found that PTTG1 expression was significantly increased in androgen-independent prostate cancer cell lines PC3, DU145 and CRPC specimens compared with that in androgen-dependent prostate cancer cell Although ADT is initially effective in suppressing tumor growth and survival, many prostate cancer patients will undergo recurrence and
progress on anti-androgen therapy, reaching a lethal stage termed castration-resistant prostate cancer (CRPC). 4 There is an urgent need to explore the mechanisms of castration resistance, which will provide better intervention strategies for CRPC patients.
Pituitary tumor transforming 1 (PTTG1) is an oncogene that was originally cloned from rat pituitary tumor cells. 5 PTTG1 overexpression can interfere with sister chromatid separation during mitosis, leading to chromosome aneuploidy. 6 Therefore, PTTG1 is involved in the development and progression in many malignancies. 7 In our previous studies, we demonstrated that PTTG1 expression was significantly increased in human prostate cancer metastasis tissue, 8 and PTTG1 promoted the proliferation of prostate cancer cells by inhibiting SMAD3. 9 Moreover, the PTTG1 mRNA expression was higher in androgen-independent prostate cancer cell lines PC3 or DU145 than that in androgen-dependent prostate cancer cell line LNCaP. 10 These results indicate that PTTG1 may play an important role in the development of castration resistance in CRPC. However, the exact role and potential mechanisms underlying the involvement of PTTG1 in CRPC are poorly clarified.
A series of studies has demonstrated that development and progression of CRPC are closely related to interleukin-6 (IL-6). IL-6 is abundantly expressed in androgen-independent prostate cancer cell lines PC3 or DU145. In contrast, IL-6 expression in androgen-dependent prostate cancer cell line LNCaP is found to be negative. 11 However, the gain of IL-6 expression in LNCaP cells through lentiviral transfection can lead these cells to be resistant to ADT. 12 In addition, IL-6 levels in plasma and serum from patients with CRPC are significantly higher than those from patients with earlier stages of prostate cancer and healthy individuals. 13 Furthermore, it has been postulated that IL-6 can regulate the expression of androgenresponsive genes in low androgen conditions and thereby contribute to the transition from hormone-dependent to CRPC. 14 As a novel downstream target gene of androgen receptor, 8 we consider whether PTTG1 can be regulated by IL-6 and is consequently involved in the development of castration resistance in CRPC. The current study aims to verify this hypothesis and further explore the potential mechanisms in IL-6/PTTG1 modulated castration resistance in CRPC.
| MATERIALS AND METHODS

| Cell culture
Human LNCaP, PC3 and DU145 prostate cancer cells were obtained from the American Type Culture Collection (ATCC, Manassas, VA, USA) and routinely tested to exclude mycoplasma contamination. All cells were maintained in RPMI 1640 supplemented with 10% FBS and 1% penicillin-streptomycin (both were purchased from GibcoLife Technologies, Grand Island, NY, USA). All cells were cultured at 37°C in 5% CO 2 and 95% air.
The plasmid containing the wild-type full-length sequence of PTTG1 and IL-6, and shRNA targeted to human PTTG1 were produced by Genema (Shanghai, China China and was performed in accordance with the provisions of the Declaration of Helsinki. 15 As previously described, 16 IHC staining was performed to investigate PTTG1 expression in the 5 paired prostate tissue specimens. Then, immunoreactive score (IRS) was calculated to measure the protein expression levels of PTTG1, as previous described. 16 Briefly, the IRS, which ranged from 0 to 12, was composited by the sub-scores for the percentage of immunoreactive cells (0-4) and immunoreactive intensity (0-3). The percent positivity was scored as "0" (<1%), "1" (1%-10%), "2"
(11%-50%), "3" (51%-80%) and "4" (>80%). The staining intensity was scored as "0" (negative), "1" (weak), "2" (moderate) and "3" 
| Tumor xenografts
All animal studies were reviewed and approved by the Animal Care 
| Luciferase assays
For luciferase assays, PTTG1 promoters, À2000/+1, À1500/+1, À1000/+1 and À500/+1 were cloned into Pmir-GLO-P luciferase reporter vector (Promega, Madison, WI, USA), and were named as Pmir/À2000, Pmir/À1500, Pmir/À1000 and Pmir/À500. The following primers were used: forward 5 0 -GAAGATCTACCTCAAAACCTCT 
| Statistical analysis
Data are presented as the mean AE SD. All experiments were performed with at least 3 independent replications. Statistical analyses were conducted using SPSS 13.0 software (SPSS, Chicago, IL, USA), and significant difference between each group was analyzed using unpaired 2-tailed Student's t tests or one-way ANOVA. Differences were considered to be statistically significant at P < .05.
| Supplemental experimental procedures
Data S1 contains a detailed description of the western blot analysis, quantitative RT-PCR, in vitro growth assays, clonogenic assays, tumor sphere formation assays and ChIP assays. Figure 1A -C). Furthermore, using IHC staining, we examined the PTTG1 expression in 5 paired prostate tissue specimens from patients with CRPC or initial prostate cancer (initial PCa), whose details were listed in Table 1 . There were no significant differences of age and Gleason score between patients with CRPC and initial PCa. Average time for ADT in patients with CRPC were 56.0 AE 23.6 months. Subsequently, we found that PTTG1 expression in prostate cancer tissues from CRPC patients was higher than that in prostate cancer tissues from initial PCa patients ( Figure 1D , E). Because of EMT is accompanied by the gain of stem cell traits in cancer cell populations, 18 we next explored whether the stem cell properties of LNCaP cells were changed by PTTG1 overexpression.
|
Firstly, we found that the protein expressions of cancer stem cell biomarkers, Sox2 and Nanog, were significantly increased by PTTG1 overexpression ( Figure 4A,B) . Then, we used tumor sphere formation assays to test the changes in sphere-forming ability of LNCaP cells induced by PTTG1 overexpression. Notably, the sphere numbers in LNCaP/PTTG1 group were significantly increased compared with that in LNCaP/Control group ( Figure 4C,D Figure 4E,F) . Taken together, these data suggested that PTTG1 plays a pivotal role in maintaining prostate cancer stem cell populations.
| Interleukin-6 increased pituitary tumor transforming gene 1 expression via activating signal transducer and activator of transcription 3 in LNCaP cells
Furthermore, we attempted to verify whether PTTG1 is regulated by IL-6 in prostate cancer and to clarify the potential mechanism. 
| 683
We first expressed IL-6 in LNCaP cells which possess negative IL-6 expression by lentiviral transfection (Figure 5A-C) . IL-6 expression significantly increased the protein and mRNA expressions of PTTG1, which can be significantly attenuated by AG490 (a STAT3 blocker, 20 lM) ( Figure 5A ,B,D). These results suggested that IL-6 may regulate PTTG1 expression via activating STAT3 in LNCaP cells.
In addition, to clarify the potential regulatory mechanism, we first analyzed regulatory regions of PTTG1 gene using a web-based tool (Consite) for finding cis-regulatory elements of STAT3 in genomic sequences. We found some putative cis-regulatory elements of STAT3 binding site in the PTTG1 promoter region ( Figure 5E ). Then, plasmids Pmir/À2000, Pmir/À1500, Pmir/À1000 and Pmir/À500
were transfected into LNCaP cells in order to measure their transcriptional activities responding to IL-6 expression. Luciferase assays demonstrated that all PTTG1 promoter fragments including À2000/ +1, À1500/+1, À1000/+1 and À500/+1 exhibited strong luciferase activities responding to IL-6 expression ( Figure 5F ). These data indicated that the STAT3 response element localized in the region of À500 to +1. Moreover, one putative STAT3 binding site in the promoter region of À500 to +1 was postulated using web-based tools.
To further confirm the responsibility of this putative STAT3 binding site for IL-6 stimulated transcription, this cis-regulatory element was deleted by a special primer. As expected, the mutated promoter construct did not respond to IL-6 expression ( Figure 5G ) was used to block STAT3 in DU145 cells. We confirmed that DU145 cells were resistant to 5 lM bicalutamide treatment. However, the combined application with bicalutamide and AG490 significantly reduced the colony numbers of DU145 cells compared with that of DU145 cells treated with single bicalutamide or AG490 (Figure 6A,B) . Consistently, we detected that DU145 cells received the combined application with bicalutamide and AG490 possessed lower cell survival rate than that treated with single bicalutamide or AG490 ( Figure 6C ).
| DISCUSSION
In the present study, we found that PTTG1 expression was significantly increased in androgen-independent prostate cancer cell lines In breast cancer, PTTG1 expression in specimens from ER-positive breast cancer patients who recurred after tamoxifen treatment is found to be significantly increased compared with specimens from patients who did not. 19 Moreover, in prostate cancer, PTTG1 overexpression is an unfavorable prognostic factor for progression in advanced prostate cancer receiving hormone therapy. 20 In the present study, we also found that PTTG1 expression in specimens from CRPC patients was significantly higher than that in specimens from initial PCa patients. Moreover, we reconfirmed the androgen-inde- Moreover, Piyush et al 24 have successfully identified agents with specific toxicity for epithelial CSC using high-throughput chemical screening. In the current study, we demonstrated that PTTG1 overexpression significantly enhanced the sphere-forming ability and increased CSC population in LNCaP cells. Also, the expressions of Sox2 and Nanog which can regulate the gain of CSC phenotypes and properties in tumor cells 22 were significantly increased due to PTTG1 overexpression. These data suggest that PTTG1 can affect the development of CRPC via improving CSC stemness. To our knowledge, EMT also plays a pivotal role in the development of CRPC. 22 EMT is a developmental process that epithelial-derived tumor cells reduced intercellular adhesion and acquired a migratory and invasive mesenchymal phenotype. 25, 26 Therefore, it has been proved that induction of an EMT in human mammary epithelial cells results in the acquisition of epithelial stem-cell properties. 18 In our present study, we detected that after PTTG1 overexpression, the expression of E-cadherin (epithelial marker) was downregulated and the expressions of N-cadherin, Vimentin (mesenchymal markers) and Snail (transcriptional repressors of E-cadherin) were upregulated, which demonstrated the induction of EMT. In a previous study, it had been shown that PTTG1 can induce EMT and promote expansion of cancer stem cell population in breast cancer. 27 Taken together, we suggest that PTTG1 can regulate the CSC stemness via inducing EMT, and facilitate the development of CRPC.
Subsequently, we tried to clarify the potential regulatory mechanism underlying the involvement of PTTG1 in CRPC. We focused on a pleiotropic cytokine IL-6 due to its important role in the progression of CRPC. 14 As we know, the effect of IL-6 on tumor cell proliferation and metastasis is mediated by STAT3 activation. 28, 29 In our study, we found that IL-6 increased PTTG1 expression via activating STAT3 in LNCaP cells. This result is consistent with that IL-6 upregulates PTTG1 expression via activating STAT3 in colorectal cancer. 30 Meanwhile, we detected that STAT3 binds to special cis-acting element on the region À500 to +1 of PTTG1 promoter. However, in colorectal cancer, STAT3 binding site is located on the region À2642 to À1717 of PTTG1 promoter. 30 These results suggest that STAT3 can regulate PTTG1 expression by binding to different site of PTTG1 promoter in various cancers. Moreover, in accordance with a previous report by others that AG490 reversed the enzalutamide resistance in LNCaP-s17 Cells which is resistant to ADT, 31 we also found that STAT3 inhibition by AG490 significantly resensitized the DU145 cells to bicalutamide treatment. In addition, overexpression of constitutively active STAT3 in LNCaP cells can induce resistance to ADT and knockdown of STAT3 expression can restore the sensitivity of LNCaP-s17 cells to enzalutamide treatment. 31, 32 These data reveal the crucial role of STAT3 in development of ADT resistance.
Taken together, we speculate that IL-6/STAT3 may critically modulate the development of CRPC via regulating PTTG1 expression. Furthermore, more recent studies have suggested that IL-6/STAT3 activation is involved in EMT induction and stem-cell properties acquisition in many cancers, [33] [34] [35] [36] further proving that PTTG1 can be regulated by IL-6/STAT3 and play its important role in CRPC via inducing EMT and improving CSC stemness.
Although, our findings illustrate a causative link between PTTG1
and EMT, as well as the gain of stem-cell properties in prostate cancer cells, we can't conclude that whether this link is ascribe to direct protein interaction or indirect regulation by other factors. In breast cancer, PTTG1 can induce EMT via PI3K/AKT signaling. 27 In ovarian epithelial cancer, such effects of PTTG1 are achieved by regulating TGF-b. 37 Therefore, more in-depth studies are required to uncover the mechanism underlying the regulation of EMT and the gain of stem-cell properties in prostate cancer cells by PTTG1.
In conclusion, our study has demonstrated that PTTG1 is overexpressed in androgen independent prostate cancer cell lines and CRPC specimens. Furthermore, we found that, as a response gene of IL-6/STAT3, PTTG1 can promote the resistance to ADT via inducing EMT and improving prostate CSC stemness. These results suggest that PTTG1 plays a vital role in CRPC and that PTTG1 can be regarded as a novel therapeutic target for CRPC.
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